Changes of number of shares and votes in BioPorto A/S
June 24, 2024
Announcement no. 15
Changes of number of shares and votes in BioPorto A/S.
Completion of share capital increase
The Board of Directors of BioPorto A/S (“BioPorto” og the “Company”) decided on June 17, 2024 to issue 50,000,000 new shares in a private placement to existing larger shareholders, new professional investors, board members and the management team (company announcement no. 13 of June 17, 2024).
Completion of the issue
BioPorto has now received the full subscription amount and the capital increase of in total nominally DKK 50,000,000 has been registered and completed with the Danish Business Authority.
BioPorto’s gross proceeds from the issue will amount to DKK 81,400,000 equivalent to approx. USD 11.7 million. The new shares are equivalent to 13.17% of BioPorto’s registered share capital prior to the share capital increase and is exempt from the requirement to publish a prospectus.
Admission to trading and official listing
The new shares have the same rights as the existing shares. The new shares are entitled to dividend from the time when the share capital increase is registered with the Danish Business Authority. The new shares will as soon as possible be admitted to trading and official listing on Nasdaq Copenhagen A/S under the Company’s permanent ISIN-code (DK0011048619).
Share capital and votes
Pursuant to section 32 of the Danish Capital Markets Act, BioPorto’s nominal share capital amounts to DKK 429,670,461, consisting of 429,670,461 shares of DKK 1.00 equivalent to 429,670,461 votes. BioPorto’s Articles of Association have been updated accordingly and are available on the Company’s website.
To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on /investor-contact/.
For inquiries, please contact
Investor Relations
Tim Eriksen, ,
Claus Thestrup, HC Andersen Capital, ,
Ashley R. Robinson, LifeSci Advisors, ,
About Acute Kidney Injury
Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: /aki/.
About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.
BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit
Attachment
